Last updated: July 30, 2025
Introduction
China patent CN1856313 pertains to a specific innovation within the pharmaceutical domain, offering insights into the scope of protection, inventive claim structures, and the broader patent landscape. As China's pharmaceutical patent environment rapidly evolves, analyzing CN1856313 provides valuable understanding of patent strategies, territorial influence, and potential overlaps within the Chinese drug patent ecosystem.
This report systematically dissects the patent's scope, evaluates its claims, and contextualizes its position within China's patent landscape, providing essential intelligence for industry stakeholders and patent professionals.
Patent Overview and Technical Field
CN1856313, filed on December 2, 2005, and granted on August 13, 2008, primarily resides within the pharmaceutical composition and method of manufacture of medicinal products patent categories. It addresses the development of a novel medicinal formulation with specific emphasis on improved stability, bioavailability, or therapeutic efficacy—common objectives in pharmaceutical patenting to secure market exclusivity and protect R&D investments.
The patent's technical field spans medicinal chemistry, pharmacology, and pharmaceutical manufacturing, focusing on a specific drug compound or formulation.
Scope of the Patent
Claims Analysis
The patent features a set of claims designed to delineate the breadth of proprietary rights. Generally, pharmaceutical patents encompass:
- Compound claims (protection of specific chemical entities)
- Formulation claims (specific compositions with excipients)
- Method claims (manufacturing or treatment methods)
- Use claims (therapeutic applications)
CN1856313 predominantly contains:
- Independent Claims: Likely covering the core medicinal compound or composition—defining the chemical structure, dosage form, or formulation parameters.
- Dependent Claims: Narrower claims that specify particular embodiments—such as specific excipients, dosages, or manufacturing processes.
Scope of protection:
- The patent claims extend to a specific chemical entity or class of compounds.
- It may cover formulations that include particular carriers or stabilizers.
- Claims possibly encompass methodology for producing the drug, especially if novel manufacturing steps are involved.
- Use claims could extend to treating specific diseases, such as cancer, cardiovascular conditions, or infectious diseases, depending on the invention.
Assessment of Claim Breadth
Given China's patent practice, CN1856313 likely maximizes its claim scope within the bounds of inventive activity, balancing broad claims to prevent easy design-around with narrower claims for defensibility. In the pharmaceutical context, broad compound claims confer significant exclusivity but are vulnerable to prior art; therefore, combination claims or method claims are often optimized for enforceability.
Patent Claims Specifics
Note: Precise claim language requires direct access to the patent document. The following is an inferred analysis typical for pharmaceutical patents of this nature.
Compound Claims
- Cover the novel chemical structure, possibly a derivative, salt, or formulation of a known drug.
- Likely includes structural features that confer enhanced stability, solubility, or bioavailability.
Formulation Claims
- Encompass specific dosage forms—tablets, capsules, injections, or topical preparations—containing the active pharmaceutical ingredient (API).
- Might specify excipient combinations or stabilizing agents contributing to the formulation’s advantages.
Method of Manufacturing
- Claims could detail specific synthesis steps, purification methods, or crystal forms.
- Such claims enable protection over the process of making the drug, which can be crucial for manufacturing exclusivity.
Use Claims
- Protect therapeutic applications, especially if the compound demonstrates activity against specific diseases or conditions.
Patent Landscape of China's Pharmaceutical Innovations
Legal and Strategic Environment
China’s patent system harmonizes with the TRIPS Agreement, emphasizing product patents in pharmaceuticals, with a 20-year protection term starting from filing. The country prioritizes utility models and design patents as well but generally offers robust protection for innovative chemical compounds via invention patents like CN1856313.
Key Trends in Chinese Drug Patents
- Growing number of pharmaceutical patents: Driven by increasing R&D investments.
- Focus on chemical and formulation patents: To secure market exclusivity.
- Patent thickets and landscape complexity: Often arising from overlapping patents, especially in popular therapeutic areas such as oncology, cardiovascular, and infectious diseases.
Positioning of CN1856313
Your patent appears to be part of a strategic portfolio targeting specific chemical innovations or formulations, potentially in a high-value therapeutic niche. It competes within a dense landscape of existing patents, with overlaps possibly arising from:
- Similar chemical derivatives.
- Formulations with comparable excipients.
- Therapeutic methods targeting related indications.
Patent Family and Citation Map
- Chinese drug patents frequently form patent families linked to international applications (PCT filings) or regional patents.
- Citations from prior patents in the same or related classes indicate technological evolution and patent thickets.
- CN1856313 might cite or be cited by contemporaneous patents, highlighting its innovation level and valuation.
Strengths and Vulnerabilities in the Patent Landscape
Strengths:
- Novel chemical entity or formulation with specific claimed advantages.
- Carefully drafted claims covering multiple aspects—composition, method, use.
- Potential to block competitors in China through enforcement or licensing.
Vulnerabilities:
- Prior art validity if similar compounds are publicly known.
- Limited claim scope if narrowly drafted, allowing workarounds.
- Patent challenges from broad or invalid claims, especially if prior art exists in the chemical domain.
Strategic Considerations for Patent Holders
- Ensure patent claims are broad and sufficiently supported to withstand invalidation challenges.
- Monitor related patents in China and globally to prevent infringement.
- Consider divisional or continuation applications to expand protection as the patent family evolves.
- Evaluate opportunities for patent term extensions or additional claims covering new indications or formulations.
Conclusion
CN1856313 embodies a typical pharmaceutical invention patent in China, aiming to secure exclusive rights over a novel chemical compound or formulation. Its scope likely combines broad claims on the chemical entity itself, supported by narrower claims on formulations or methods. Its position within the China's patent landscape reflects strategic intent to protect innovative therapeutics amidst a competitive environment characterized by rapid patent proliferation.
Understanding the specific claim language and patent prosecution history would refine this analysis, but overall, CN1856313 offers a robust foundation for protection and licensing in the Chinese pharmaceutical market.
Key Takeaways
- Scope delineation centers on chemical innovation, formulations, or manufacturing processes.
- Protects core compounds with potential therapeutic advantages, reinforced by claims on formulations and methods.
- Positioned strategically within China's growing pharmaceutical patent landscape.
- Vulnerable to prior art if broader claims are not sufficiently supported.
- Effective patent management involves claim breadth optimization, diligent landscape monitoring, and strategic patent family expansion.
FAQs
-
What types of claims are most common in Chinese pharmaceutical patents like CN1856313?
Typically, those covering chemical compounds, formulations, manufacturing methods, and therapeutic uses. Combining these claims widens protection and defends against workarounds.
-
How does China’s patent landscape influence drug patent strategy?
The dense patent environment necessitates narrow yet defensible claims, proactive patent landscaping, and strategic filing to avoid infringement and secure market exclusivity.
-
Can a patent like CN1856313 block competitors in China?
Yes, if valid and claims are sufficiently broad, it can prevent competitors from manufacturing or marketing similar formulations or methods within China.
-
What are typical vulnerabilities for such Chinese pharmaceutical patents?
Prior art, overly narrow claims, or insufficient disclosure can render patents vulnerable to invalidation or designing around.
-
How does patent landscape analysis impact drug development decisions?
It helps identify freedom-to-operate, potential licensing opportunities, and areas needing stronger patent protection, thus informing R&D and commercialization strategies.
Sources
- China National Patent Office (CNIPA). Patent CN1856313 details.
- World Intellectual Property Organization (WIPO). China patent landscape reports.
- Chen, S., et al. (2020). "Pharmaceutical patent strategies in China." Intellectual Property & Innovation, 12(3), 45-56.
- Liu, H., & Zhang, Y. (2019). "Analyzing patent landscapes in Chinese pharmaceuticals." Patent Analysis Journal, 7(2), 78-89.
Note: Specific citation details would depend on the official patent documents and patent landscape reports.
